Trigeminal Neuralgia (Tic Douloureux) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Trigeminal Neuralgia (Tic Douloureux) – Drugs In Development, 2024 report and make more profitable business decisions.
Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from the face to the brain. Symptoms include spontaneous attacks of pain or attacks triggered by things such as touching the face, chewing, speaking, and brushing teeth; pain in areas supplied by the trigeminal nerve, including the cheek, jaw, teeth, gums, lips, or less often the eye and forehead.
The Trigeminal Neuralgia (Tic Douloureux) drugs in development market research report provide comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Tic Douloureux), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Trigeminal Neuralgia (Tic Douloureux) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Trigeminal Neuralgia (Tic Douloureux) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 15 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Trigeminal Neuralgia (Tic Douloureux) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Trigeminal Neuralgia (Tic Douloureux) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Trigeminal Neuralgia (Tic Douloureux) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acasti Pharma IncAmgen Inc
Coda Biotherapeutics Inc
Duke University
Hoba Therapeutics ApS
Initiator Pharma AS
InMed Pharmaceuticals Inc
Kriya Therapeutics Inc
Nobelpharma Co Ltd
Noema Pharma AG
Noveome Biotherapeutics Inc
OliPass Corporation
Praxis Precision Medicines Inc
University of Wisconsin-Milwaukee
USA Elixiria Biotech Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Trigeminal Neuralgia (Tic Douloureux) reports